Differences in serological IgA responses to recombinant baculovirus derived human papillomavirus E2 protein in the natural history of cervical neoplasia

British Journal of Cancer

Volumn 75, Issue 8, 1997, Pages 1144-1150

  Rocha Zavaleta, L ^a   Jordan, D ^a   Pepper, S ^a   Corbitt, G ^b   Clarke, F ^a   Maitland, N J ^c   Sanders, C M ^c   Arrand, J R ^a   Stern, P L ^a   Stacey, S N ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Baculovirus; Cervical neoplasia; E2 protein; Human papillomavirus; Serology

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MUTANT PROTEIN; POLYHISTIDINE; VIRUS PROTEIN;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ANTIBODY PRODUCTION; ARTICLE; BACULOVIRUS; CANCER IMMUNOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS RECOMBINANT; WART VIRUS;

EID: 8044252154     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.197     Document Type: Article

References (32)

1. Benton C, Shahdullah H and Hunter JAA (1992) Human papillomavirus in the immunocompromised. Papillomavirus Report 3: 23-26
2. Buckley CH, Butler EB and Fox H (1982) Cervical intraepithelial neoplasia. J Clin Pathol 35: 1-13
3. Cullen AP, Reid R, Campion M and Lorincz AT (1991) Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 65: 606-612
4. Davies H (1994) Immunological aspects of cutaneous warts. In Human Papillomavirus and Cervical Cancer, Stern PL and Stanley MA. (eds), pp. 192-196. Oxford University Press: Oxford
5. Dillner J, Dillner L, Robb J, Willems J, Jones I, Lancaster W, Smith R and Lerner R (1989) A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia. Proc Natl Acad Sci USA 86: 3838-3841
6. Dillner J, Lenner P, Lehtinen M, Eklund C, Heino P, Wiklund F, Hallmans G and Stendahl U (1994) A population-based seroepidemiological study of cervical cancer. Cancer Res 54: 134-141
7. Dillner J, Wiklund F, Lenner P, Eklund C, Frederiksson SV, Schiller JT, Hibma M, Hallmans G and Stendahl U (1995) Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer 60: 377-382
8. Dillner L, Zellbi A, Åvall-Lundqvist E, Heino P, Eklund C, Pettersson CA, Forslund O, Hansson BG, Grandien M, Bistoletti P and Dillner J (1995) Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer. Cancer Detect Prev 19: 381-393
9. Fuchs PG, Girardi F and Pfister H (1989) Human papillomavirus 16 DNA in cervical cancers and in lymph nodes of cervical cancer patients: a diagnostic marker for early metastases? Int J Cancer 43: 41-44
10. Galloway DA (1994) Papillomavirus Capsids: a new approach to identify serological markers of HPV infection. J Natl Cancer Inst 86: 474-475
11. Gauthier J-M, Dillner J and Yaniv M (1991) Structural analysis of the human papillomavirus type 16-E2 transactivator with antipeptide antibodies reveals a high mobility region linking the transactivation and the DNA binding domains. Nucl Acids Res 19: 7073-7079
12. Gissmann L and Muller M (1994) Serological immune response to HPV. In Human Papillomavirus and Cervical Cancer, Stern PL and Stanley MA. (eds), pp. 132-144. Oxford University Press: Oxford
13. King LA and Possee RD (1992) The Baculovirus Expression System: A Laboratory Guide. Chapman & Hall: London
14. Kochel HG, Sievert K, Monazahian M, Mittelstadt DA, Teichmann A and Thomssen R (1991) Antibodies to human papillomavirus type-16 in human sera as revealed by the use of prokaryotically expressed viral gene products. Virology 182: 644-654
15. Lehtinen M, Leminen A, Paavonen J, Lehtovirta P, Hyoty H, Vesterinen E and Dillner J (1992a) Predominance of serum antibodies to synthetic peptide stemming from HPV 18 open reading frame E2 in cervical adenocarcinoma. J Clin Pathol 45: 494-497
16. Lehtinen M, Leminen A, Kuoppala T, Tiikkainen M, Lehtinen T, Lehtovirta P, Punnonen R, Vesterinen H and Paavonen J (1992b) Pre- and post-treatment serum antibody responses to HPV 16 E2 and HSV 2 ICP8 proteins in women with cervical carcinoma. J Med Virol 37: 180-186
17. Lenner P, Dillner J, Wiklund F, Hallmans G and Stendahl U (1995) Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix. Cancer Immunol Immunother 40: 201-205
18. Mann VM, Loo De Lao S, Brenes M, Brinton LA, Rawls JA, Green M. Reeves WC and Rawls WE (1990) Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls. Cancer Res 50: 7815-7819
19. Matsukura T, Koi S and Sugase M (1989) Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 172: 63-72
20. Muller M, Viscidi RP, Sun Y, Guerrero H, Hill PM, Shah F, Bosch FX, Munoz N, Gissmann L and Shah KV (1992) Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. Virology 187: 508-514
21. Munoz N, Bosch FX, De Sanjose S, Tafur L, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N, Gonzalez LC, Kaldor JM, Guerrero E, Lorincz A, Santamaria M, Alonso De Ruiz P, Aristizabal N and Shah K (1992) The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 52: 743-749
22. Nindl I, Benitez BL, Berumen J, Farmanara N, Fisher S, Gross G, Lopez CL, Muller M, Tommasino M, Vazquez-Curiel A and Gissmann L (1994) Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients. Arch Virol 137: 341-353
23. Reeves WC, Rawls JA, Green M and Rawls WE (1990) Antibodies to human papillomavirus type 16 in patients with cervical neoplasia. Lancet 335: 551-552
24. Sanders CM, Stern PL and Maitland NJ (1995) Characterization of human papillomavirus type 16 E2 protein and subdomains expressed in insect cells. Virology 211: 418-433
25. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK and Manos MM (1993) Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85: 958-964
26. Seedorf K, Krammer G, Durst M, Suhai S and Rowekamp WG (1985) Human papillomavirus type 16 DNA sequence. Virology 145: 181-185
27. Stacey SN, Bartholomew JS, Ghosh A, Stern PL, Mackett M and Arrand JR (1992) Expression of human papillomavirus type 16 E6 protein by recombinant baculovirus and use for detection of anti-E6 antibodies in human sera. J Gen Virol 73: 2337-2345
28. Stacey SN, Eklund C, Jordan D, Smith NK, Stern PL, Dillner J and Arrand JR (1994) Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies. Oncogene 9: 635-645
29. Stanley MA, Coleman N and Chambers M (1994) The host response to lesions induced by human papillomavirus. In Vaccines Against Virally Induced Cancers: Ciba Foundation Symposium 187, Chadwick DJ and Marsh J. (eds). pp. 21-44. John Wiley: Chichester
30. Turek LP (1994) The structure, function, and regulation of papillomaviral genes in infection and cervical cancer. Adv Virus Res 44: 305-356
31. Viscidi RP, Sun Y, Tsuzaki B, Bosch FX, Munoz N and Shah KV (1993) Serologic response in human papillomavirus-associated invasive cervical cancer, Int J Cancer 55: 780-784
32. Walboomers JMM, De Roda Husman A-M, Van Den Brule AJC, Snijders PJF and Meijer CJLM (1994) Detection of genital human papillomavirus infections: Critical review of methods and prevalence studies in relation to cervical cancer. In Human Papillomavirus and Cervical Cancer, Stern PL and Stanley MA. (eds), pp. 41-71. Oxford University Press: Oxford